Cyclooxygenase-2 (COX-2): first immunohistochernical marker distinguishing early cutaneous melanomas from benign melanocytic skin turnours

We have reported recently that changes in expression level of COX-2 are correlated with development and progression of human melanoma. In this study, we investigated whether the COX-2 expression level might be a useful immunohistochemical marker for distinguishing cutaneous melanomas from benign melanocytic lesions. Up to now, immunohistochemical markers have not ensured satisfactory sensitivity and specificity of differential pathologic diagnosis of melanoma. The expression of COX-2 was determined immunohistochemically in formalin-fixed, paraffin-embedded specimens of 33 early Clark I/II melanomas and 58 naevi. Mean COX-2 expression in melanomas was significantly stronger than in naevi (P approximate to 10(-13)). A simple diagnostic algorithm using threshold values of the COX-2 expression level allows for differentiation between early melanomas and naevi with high sensitivity (Se) and specificity (Sp) (for Se between 91 and 100%, Sp values change between 96.5 and 51.7%). Areas under the receiver operating characteristic curves were, respectively, 0.97 +/- 0.02 and 0.86 +/- 0.04 for the COX-2 expression in central and border regions of the lesions. For all the melanomas (not only the early ones), the respective areas under the ROC curve values were 0.98 +/- 0.01 and 0.97 +/- 0.02. In conclusion, COX-2 is the first immunolhistochemical marker that allows the distinguishing of early melanomas from benign melanocytic lesions with both high sensitivity and specificity. Melanoma Res 17:139-145 (C) 2007 Lippincott Williams & Wilkins.